Amgen Inc
BMV:AMGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Amgen Inc
BMV:AMGN
|
US |
|
S
|
Sumitomo Heavy Industries Ltd
DUS:SSM1
|
JP |
|
T
|
Tiger Brands Ltd
JSE:TBS
|
ZA |
Intrinsic Value
The intrinsic value of 
Amgen Inc (AMGN) under the Base Case is 6 937.83 MXN per share.
Compared with the current market price of 8 390 MXN, the stock appears
Overvalued by 17% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Amgen Does
Amgen is a biotechnology company that discovers, develops, manufactures, and sells prescription medicines for serious diseases. Its drugs focus on areas such as cancer, bone health, inflammation, heart disease, and rare conditions. The company’s main customers are doctors, hospitals, specialty pharmacies, and health systems that prescribe or dispense these treatments to patients.
- Headquarters
- United States of America US
- Employees
- 31 500
- IPO date
- Jun 17, 1983
Amgen has a wide economic moat
Patents and exclusive rights to sell approved medicines prevent rivals from freely copying important Amgen treatments. These protections span a broad range of medicines, allowing Amgen to defend profits across several diseases rather than depend on a single drug.
Read the full moat analysis
Revenue & Expenses Breakdown
Amgen Inc
Earnings Waterfall
Amgen Inc
The intrinsic value for Amgen Inc (AMGN) under the Base Case is 6 937.83 MXN.
Compared with the current market price of 8 390 MXN, the stock appears Overvalued by 17% .